NEW YORK — Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) said on Tuesday that it has committed up to $13.8 million in funding to Novel Microdevices to support the company's development of a point-of-care test for sexually transmitted bacterial infections.